World-first targeted throat probiotic hits the Australian market

We hear a lot about the benefits of good bacteria for gut health, but did you know that the oral cavity is home to over 700 species of bacteria and also plays a critical role in supporting the body’s immune defences and overall health?

Introducing a new approach to throat health – Blis Probiotics. The range has been developed with the unique BLIS K12™ strain (Streptococcus salivarius K12). Unlike most probiotics, which work in the gut, BLIS K12 specifically targets and protects the gateway to the body — the mouth and throat.

The BLIS K12 strain was discovered in New Zealand by Professor John Tagg.

He made it his lifelong mission to find a way to help prevent the occurrence of tonsillitis in adults and children after suffering from serious illness in his youth which started with a strep throat infection.

The strain was isolated from the mouth of a healthy child in New Zealand after Professor Tagg discovered that those who had the naturally occurring good bacteria (Streptococcus salivarius ), were less susceptible to throat infections.

He saw that the strain inhibited the bad bacteria that is responsible for most throat infections (Streptococcus pyogenes ) and helped support overall immunity by colonising the oral cavity with good bacteria.

iNova Pharmaceuticals will be launching the Blis Probiotics brand in Australia this week, with products hitting shelves in pharmacies from April.

The brand was launched to trade at this year’s APP Conference with a speaker session by Dr. John Hale, CTO of Blis Technologies, and will be supported by an exciting consumer and trade marketing program.

For more information, please contact iNova at 1800 630 056 (FREE CALL), or email customerservice@inovapharma.com.